[go: up one dir, main page]

CA3039089C - Procedes d'identification d'immunogenes par ciblage de mutations improbables - Google Patents

Procedes d'identification d'immunogenes par ciblage de mutations improbables

Info

Publication number
CA3039089C
CA3039089C CA3039089A CA3039089A CA3039089C CA 3039089 C CA3039089 C CA 3039089C CA 3039089 A CA3039089 A CA 3039089A CA 3039089 A CA3039089 A CA 3039089A CA 3039089 C CA3039089 C CA 3039089C
Authority
CA
Canada
Prior art keywords
antibody
hiv
seq
improbable
mutations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3039089A
Other languages
English (en)
Other versions
CA3039089A1 (fr
Inventor
Barton F. Haynes
Kevin J. WIEHE
Mattia Bonsignori
Original Assignee
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2017/020823 external-priority patent/WO2017152146A2/fr
Application filed by Duke University filed Critical Duke University
Priority claimed from PCT/US2017/054956 external-priority patent/WO2018067580A1/fr
Publication of CA3039089A1 publication Critical patent/CA3039089A1/fr
Application granted granted Critical
Publication of CA3039089C publication Critical patent/CA3039089C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

L'invention concerne des procédés pour identifier des mutations improbables dans le domaine variable de chaîne lourde ou de chaîne légère d'un anticorps, des procédés pour identifier des antigènes qui se lient à des anticorps comprenant de telles mutations impropres, et des procédés d'utilisation de tels antigènes pour induire des réponses immunitaires.
CA3039089A 2016-10-03 2017-10-03 Procedes d'identification d'immunogenes par ciblage de mutations improbables Active CA3039089C (fr)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201662403649P 2016-10-03 2016-10-03
US201662403635P 2016-10-03 2016-10-03
US62/403,649 2016-10-03
US62/403,635 2016-10-03
PCT/US2017/020823 WO2017152146A2 (fr) 2016-03-03 2017-03-03 Compositions et procédés pour induire des anticorps du vih-1
USPCT/US2017/020823 2017-03-03
US201762476985P 2017-03-27 2017-03-27
US62/476,985 2017-03-27
US201762489250P 2017-04-24 2017-04-24
US62/489,250 2017-04-24
PCT/US2017/054956 WO2018067580A1 (fr) 2016-10-03 2017-10-03 Procédés d'identification d'immunogènes par ciblage de mutations improbables

Publications (2)

Publication Number Publication Date
CA3039089A1 CA3039089A1 (fr) 2018-04-12
CA3039089C true CA3039089C (fr) 2025-12-30

Family

ID=

Similar Documents

Publication Publication Date Title
US11746143B2 (en) Methods to identify immunogens by targeting improbable mutations
Roark et al. Recapitulation of HIV-1 Env-antibody coevolution in macaques leading to neutralization breadth
Doria-Rose et al. New member of the V1V2-directed CAP256-VRC26 lineage that shows increased breadth and exceptional potency
Krebs et al. Longitudinal analysis reveals early development of three MPER-directed neutralizing antibody lineages from an HIV-1-infected individual
US11884704B2 (en) Compositions comprising HIV envelopes to induce CH235 lineage antibodies
US11246920B2 (en) Compositions and methods for inducing HIV-1 antibodies
Cale et al. Virus-like particles identify an HIV V1V2 apex-binding neutralizing antibody that lacks a protruding loop
Murphy et al. Viral escape from neutralizing antibodies in early subtype A HIV-1 infection drives an increase in autologous neutralization breadth
CA3055204A1 (fr) Compositions et procedes pour induire des anticorps anti-vih-1
US11318197B2 (en) Compositions and methods for inducing HIV-1 antibodies
Williams et al. Identification of HIV gp41-specific antibodies that mediate killing of infected cells
Malherbe et al. Envelope variants circulating as initial neutralization breadth developed in two HIV-infected subjects stimulate multiclade neutralizing antibodies in rabbits
van Eeden et al. V2-directed vaccine-like antibodies from HIV-1 infection identify an additional K169-binding light chain motif with broad ADCC activity
He et al. Hidden lineage complexity of glycan-dependent HIV-1 broadly neutralizing antibodies uncovered by digital panning and native-like gp140 trimer
Kuwata et al. Conformational epitope consisting of the V3 and V4 loops as a target for potent and broad neutralization of simian immunodeficiency viruses
Crooks et al. Engineering well-expressed, V2-immunofocusing HIV-1 envelope glycoprotein membrane trimers for use in heterologous prime-boost vaccine regimens
Gorman et al. Isolation and structure of an antibody that fully neutralizes isolate SIVmac239 reveals functional similarity of SIV and HIV glycan shields
Qin et al. Characterization of a large panel of rabbit monoclonal antibodies against HIV-1 gp120 and isolation of novel neutralizing antibodies against the V3 loop
Mathew et al. Display of the HIV envelope protein at the yeast cell surface for immunogen development
Morris et al. Transient glycan shield reduction induces CD4-binding site broadly neutralizing antibodies in SHIV-infected macaques
Williams et al. Vaccine induction in humans of polyclonal HIV-1 heterologous neutralizing antibodies
CA3039089C (fr) Procedes d'identification d'immunogenes par ciblage de mutations improbables
Joyce et al. Antigen pressure from two founder viruses induces multiple insertions at a single antibody position to generate broadly neutralizing HIV antibodies
Zhu et al. Identification of variant HIV envelope proteins with enhanced affinities for precursors to anti-gp41 broadly neutralizing antibodies
Gao et al. Augmenting Neutralization breadth against Diverse HIV-1 by increasing the Ab-Ag interface on V2